Form 4: Soleno Therapeutics Executive Michael F. Huang Reports Acquisition and Disposal of Common Stock
SEC Form 4 Filing
Michael F. Huang, Sr. VP of Clinical Development at Soleno Therapeutics, reports acquiring 35,000 shares of common stock and disposing of an unspecified amount through restricted stock units.
Summary
- On July 17, 2024, Michael F. Huang, Sr. VP of Clinical Development at Soleno Therapeutics, reported a transaction involving the company's common stock.
- Huang acquired 35,000 shares of common stock.
- The filing also indicates a disposal of an unspecified amount of common stock.
- These transactions involve restricted stock units (RSUs), each representing a contingent right to receive one share of common stock.
- 50% of the RSUs vest upon NDA Approval Date and the remaining 50% vest one year after the NDA Approval Date, contingent upon continued service.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting stock transactions by a company insider, with neutral sentiment.
Future Outlook
The vesting of the RSUs is contingent upon the NDA Approval Date and continued service of the reporting person.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to investors.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider activity.
Key Dates
| Date | Description |
|---|---|
| 07/17/2024 | Date of transaction involving acquisition and disposal of common stock. |
| 07/19/2024 | Date of signature by Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.